1. Home
  2. ADUS vs NTLA Comparison

ADUS vs NTLA Comparison

Compare ADUS & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Addus HomeCare Corporation

ADUS

Addus HomeCare Corporation

HOLD

Current Price

$107.54

Market Cap

2.1B

Sector

Health Care

ML Signal

HOLD

Logo Intellia Therapeutics Inc.

NTLA

Intellia Therapeutics Inc.

HOLD

Current Price

$9.01

Market Cap

986.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ADUS
NTLA
Founded
1979
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Nursing Services
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
986.9M
IPO Year
2009
2016

Fundamental Metrics

Financial Performance
Metric
ADUS
NTLA
Price
$107.54
$9.01
Analyst Decision
Buy
Buy
Analyst Count
11
22
Target Price
$138.73
$19.83
AVG Volume (30 Days)
156.1K
3.5M
Earning Date
11-03-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
6.76
N/A
EPS
4.66
N/A
Revenue
$1,346,596,000.00
$57,528,000.00
Revenue This Year
$25.50
$1.96
Revenue Next Year
$7.11
N/A
P/E Ratio
$23.31
N/A
Revenue Growth
18.77
33.52
52 Week Low
$88.96
$5.90
52 Week High
$136.72
$28.25

Technical Indicators

Market Signals
Indicator
ADUS
NTLA
Relative Strength Index (RSI) 34.08 42.04
Support Level $110.12 $8.98
Resistance Level $111.57 $9.62
Average True Range (ATR) 2.22 0.43
MACD -0.56 0.17
Stochastic Oscillator 1.81 25.23

Price Performance

Historical Comparison
ADUS
NTLA

About ADUS Addus HomeCare Corporation

Addus HomeCare Corp is engaged in the provision of in-home personal care services. It operates through the segments such as Personal care segment, which is a key revenue driver, provides non-medical assistance with activities of daily living, mainly to persons who are at risk of hospitalization or institutionalization, such as the elderly, chronically ill and disabled. The Hospice segment provides physical, emotional and spiritual care for people who are terminally ill and their families. Its Home health segment provides services that are medical in nature to those individuals who may require assistance during an illness or after surgery.

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Share on Social Networks: